Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Raises Q4 and 2020 Revenue, Earnings Guidance

NEW YORK – Thermo Fisher Scientific said in a regulatory filing on Tuesday that it is raising its fourth quarter and full-year revenue and earnings guidance.

According to a document filed with the US Securities and Exchange Commission, the company now expects organic revenues to grow 40 percent year over year in Q4, driven by its base business and sales related to the COVID-19 response. In October, the company had said it expected 29 percent organic revenue growth for the quarter. For full-year 2020, the firm now anticipates year-over-year organic revenue growth of 22 percent compared to a previous 20 percent.

In addition, Thermo Fisher now anticipates full-year 2020 adjusted earnings per share to grow 55 percent year over year to $19.17. Previously, the firm had expected adjusted EPS to grow 48 percent year over year to $18.27.

In afternoon trading on the New York Stock Exchange, Thermo Fisher's stock was up almost 2 percent at $473.89 per share.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.